Erratum: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin (Oncotarget (2015) 6 (1020-1030) DOI: 10.18632/oncotarget.2741);Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin

Oncotarget

Volumn 6, Issue 2, 2015, Pages 1020-1030

  Liang, Sixian ^a   Peng, Xun ^a   Li, Xiaoli ^a   Yang, Ping ^a   Xie, Linhao ^a   Li, Yaochen ^a   Du, Caiwen ^a   Zhang, Guojun ^a  

^a CANCER HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Apoptosis; Chemosensitivity; Cisplatin; CXCR4; Triple negative breast cancer

Indexed keywords

CASPASE 3; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SHORT HAIRPIN RNA; ANTINEOPLASTIC AGENT; CXCR4 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; G2 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; IN VIVO STUDY; MOUSE; NONHUMAN; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE, INBRED BALB C; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, CXCR4; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921715930     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/ONCOTARGET.28109     Document Type: Erratum

References (48)

1. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA: the journal of the American Medical Association. 2006; 295:2492-2502.
2. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. The New England journal of medicine. 2010; 363:1938-1948.
3. De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, Lorusso V, De Placido S. Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer treatment reviews. 2010; 36:S80-86.
4. Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2012; 23:2223-2234.
5. Roy V, Pockaj B, Northfelt D, Allred J, Liu H, Nikcevich D, Mattar B, Perez E. N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26:563.
6. Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer-deciphering the heterogeneity. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20:782-790.
7. Kelland LR. Preclinical perspectives on platinum resistance. Drugs. 2000; 59:1-8 discussion 37-38.
8. Gales D, Clark C, Manne U, Samuel T. The Chemokine CXCL8 in Carcinogenesis and Drug Response. ISRN oncology. 2013; 2013:859154.
9. Farrow B, Albo D, Berger DH. The role of the tumor microenvironment in the progression of pancreatic cancer. The Journal of surgical research. 2008; 149:319-328.
10. Zlotnik A. New insights on the role of CXCR4 in cancer metastasis. The Journal of pathology. 2008; 215:211-213.
11. Sison EA, McIntyre E, Magoon D, Brown P. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML. Molecular cancer research: MCR. 2013; 11:1004-1016.
12. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, DiPersio JF. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009; 113:6206-6214.
13. Yang P, Liang SX, Huang WH, Zhang HW, Li XL, Xie LH, Du CW, Zhang GJ. Aberrant expression of CXCR4 significantly contributes to metastasis and predicts poor clinical outcome in breast cancer. Current molecular medicine. 2014; 14:174-184.
14. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer science. 2007; 98:1652-1658.
15. Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. The Journal of clinical investigation. 2013; 123:2395-2407.
16. Khalaf D, Hilton JF, Clemons M, Azoulay L, Yin H, Vandermeer L, Dent S, Hopkins S, Bouganim N. Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. Oncology letters. 2014; 7:866-870.
17. Koshy N, Quispe D, Shi R, Mansour R, Burton GV. Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast (Edinburgh, Scotland). 2010; 19:246-248.
18. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer treatment reviews. 1998; 24:331-344.
19. Reardon JT, Vaisman A, Chaney SG, Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer research. 1999; 59:3968-3971.
20. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012; 31:1869-1883.
21. Ratanaphan A. A DNA Repair BRCA1 Estrogen Receptor and Targeted Therapy in Breast Cancer. International journal of molecular sciences. 2012; 13:14898-14916.
22. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. The Journal of clinical investigation. 2007; 117:1370-1380.
23. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer research. 2010; 70:7970-7980.
24. Peled A, Tavor S. Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics. 2013; 3:34-39.
25. Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, Konoplev S, Andreeff M, Konopleva M. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009; 113:6215-6224.
26. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16:2927-2931.
27. Ying J, Xu Q, Zhang G, Liu B, Zhu L. The expression of CXCL12 and CXCR4 in gastric cancer and their correlation to lymph node metastasis. Medical oncology (Northwood, London, England). 2012; 29:1716-1722.
28. Yang SX, Loo WT, Chow LW, Yang XH, Zhan Y, Fan LJ, Zhang F, Chen L, Wang QL, Xiao HL, Wu JL, Bian XW, Jiang J. Decreased expression of C-erbB-2 and CXCR4 in breast cancer after primary chemotherapy. Journal of translational medicine. 2012; 10:S3.
29. Murakami T, Kawada K, Iwamoto M, Akagami M, Hida K, Nakanishi Y, Kanda K, Kawada M, Seno H, Taketo MM, Sakai Y. The role of CXCR3 and CXCR4 in colorectal cancer metastasis. International journal of cancer Journal international du cancer. 2013; 132:276-287.
30. Jung MJ, Rho JK, Kim YM, Jung JE, Jin YB, Ko YG, Lee JS, Lee SJ, Lee JC, Park MJ. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene. 2013; 32:209-221.
31. Sekiya R, Kajiyama H, Sakai K, Umezu T, Mizuno M, Shibata K, Yamamoto E, Fujiwara S, Nagasaka T, Kikkawa F. Expression of CXCR4 indicates poor prognosis in patients with clear cell carcinoma of the ovary. Human pathology. 2012; 43:904-910.
32. Li J, Jiang K, Qiu X, Li M, Hao Q, Wei L, Zhang W, Chen B, Xin X. Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer. BMB reports. 2014; 47:33-38.
33. Mao W, Yi X, Qin J, Tian M, Jin G. CXCL12 inhibits cortical neuron apoptosis by increasing the ratio of Bcl-2/Bax after traumatic brain injury. The International journal of neuroscience. 2014; 124:281-290.
34. Liu X, Duan B, Cheng Z, Jia X, Mao L, Fu H, Che Y, Ou L, Liu L, Kong D. SDF-1/CXCR4 axis modulates bone marrow mesenchymal stem cell apoptosis, migration and cytokine secretion. Protein & cell. 2011; 2:845-854.
35. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000; 408:307-310.
36. Muller PA, Vousden KH. p53 mutations in cancer. Nature cell biology. 2013; 15:2-8.
37. Mori E, Takahashi A, Yamakawa N, Kirita T, Ohnishi T. High LET heavy ion radiation induces p53-independent apoptosis. Journal of radiation research. 2009; 50:37-42.
38. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Seminars in cancer biology. 1993; 4:327-332.
39. Reed JC. Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell death and differentiation. 2006; 13:1378-1386.
40. MacKenzie SH, Clark AC. Targeting cell death in tumors by activating caspases. Current cancer drug targets. 2008; 8:98-109.
41. Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23:9408-9421.
42. Aziz MY, Omar AR, Subramani T, Yeap SK, Ho WY, Ismail NH, Ahmad S, Alitheen NB. Damnacanthal is a potent inducer of apoptosis with anticancer activity by stimulating p53 and p21 genes in MCF-breast cancer cells. Oncology letters. 2014; 7:1479-1484.
43. Jin J, Lin G, Huang H, Xu D, Yu H, Ma X, Zhu L, Ma D, Jiang H. Capsaicin mediates cell cycle arrest and apoptosis in human colon cancer cells via stabilizing and activating p53. International journal of biological sciences. 2014; 10:285-295.
44. Zhang XP, Liu F, Wang W. Interplay between Mdm2 and HIPK2 in the DNA damage response. Journal of the Royal Society, Interface/the Royal Society. 2014; 11:1-9.
45. Yu SY, Liao CH, Chien MH, Tsai TY, Lin JK, Weng MS. Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer. Journal of agricultural and food chemistry. 2014; 62:2085-2095.
46. Charoensinphon N, Qiu P, Dong P, Zheng J, Ngauv P, Cao Y, Li S, Ho CT, Xiao H. 5-demethyltangeretin inhibits human nonsmall cell lung cancer cell growth by inducing G2/M cell cycle arrest and apoptosis. Molecular nutrition & food research. 2013; 57:2103-2111.
47. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr., Kohn KW. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer research. 1997; 57:4285-4300.
48. Huang M, Whang P, Lewicki P, Mitchell BS. Cyclopentenyl cytosine induces senescence in breast cancer cells through the nucleolar stress response and activation of p53. Molecular pharmacology. 2011; 80:40-48.